Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention ANI Pharmaceuticals, the most common co-covered peer. Source depth averages 4 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention ANI Pharmaceuticals, the most common co-covered peer. Source depth averages 4 original sources per story, versus 2.6 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. Amneal Pharmaceuticals appears in 1 tracked Finance story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amneal Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on rare disease expansion and biosimilar adoption. The broader earnings window also features updates from Fulgent Genetics and Alpha Metallurgical, highlighting a diverse landscape of diagnostic shifts and commodity pricing.
Amneal Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
